NASDAQ · ABVC
Healthcare · Biotechnology
$0.99
Up+$0.01 (+0.51%)
Updated Nov 4, 2026, 1:48 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ABVC
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
ABVC closed at $0.99 after 21 trading sessions, up 1.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $0.99 | $1.00 | $0.9801 | $0.9851 | 31.81K |
| Nov 2, 2026 | $1.01 | $1.0499 | $0.98 | $0.9801 | 30.18K |
| Oct 30, 2026 | $1.02 | $1.02 | $1.00 | $1.00 | 20.2K |
| Oct 29, 2026 | $1.10 | $1.11 | $1.03 | $1.04 | 34.88K |
| Oct 28, 2026 | $1.05 | $1.10 | $1.03 | $1.09 | 35.41K |
| Oct 27, 2026 | $1.06 | $1.10 | $1.04 | $1.05 | 24.23K |
| Oct 26, 2026 | $1.04 | $1.07 | $1.03 | $1.05 | 36.6K |
| Oct 23, 2026 | $1.04 | $1.06 | $1.03 | $1.04 | 22.01K |
| Oct 22, 2026 | $1.02 | $1.0677 | $1.00 | $1.0473 | 45.69K |
| Oct 21, 2026 | $1.00 | $1.0176 | $0.96 | $1.00 | 49.34K |
| Oct 20, 2026 | $0.92 | $0.9899 | $0.92 | $0.93 | 11.82K |
| Oct 19, 2026 | $0.918 | $0.9417 | $0.8918 | $0.91 | 26.89K |
| Oct 16, 2026 | $0.91 | $0.945 | $0.90 | $0.9179 | 29.2K |
| Oct 15, 2026 | $1.03 | $1.05 | $0.92 | $0.9325 | 104.79K |
| Oct 14, 2026 | $1.00 | $1.03 | $0.96 | $1.02 | 55.9K |
| Oct 13, 2026 | $1.00 | $1.0182 | $0.96 | $0.979 | 119.96K |
| Oct 12, 2026 | $1.03 | $1.03 | $0.97 | $0.9798 | 95.93K |
| Oct 9, 2026 | $1.01 | $1.01 | $0.9799 | $1.00 | 41.47K |
| Oct 8, 2026 | $1.03 | $1.05 | $0.975 | $0.98 | 45.31K |
| Oct 7, 2026 | $0.9409 | $1.01 | $0.94 | $1.00 | 52.75K |
| Oct 6, 2026 | $0.9851 | $1.0083 | $0.929 | $0.97 | 92.42K |
The latest Smart Investors Daily articles mentioning ABVC.
Company
Market Activity
Research & News
ABVC research
Company profile and research snapshot.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 16, 2022 | Maxim Group | Hold | — |
No generated briefing is available yet.
Benzinga · Aug 12, 2026
On August 3, 2026, ABVC BioPharma, Inc. (the "Company") determined to postpone the previously announced distribution of ordinary shares of BioKey (Cayman), Inc. (the "Distribution"), which had been
Benzinga · Apr 6, 2026
Benzinga · Mar 30, 2026
GlobeNewswire Inc. · Apr 18, 2024
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and Oncology/Hematology, announced today that the Company's subsidiary AiBtl BioPharma Inc. acquired TT Life Company, an established player in the precision medicine industry. The acquisition includes Malaysian Import Trading Company, Direct Sales Company, and Taiwanese Direct Sales Company, which are estimated to be approximately equivalent to $8.33M. AiBtl purchased 100% shares of TT Life by swapping its 1.66M shares at $5 per share. This strategic move positions AiBtl to expand its portfolio further and accelerate innovation in the rapidly growing precision medicine market while consolidating the financials, including the revenue, profit, and cash flow, with TT Life.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ABVC.
